| First Author | De Robertis M | Year | 2015 |
| Journal | Oncotarget | Volume | 6 |
| Issue | 38 | Pages | 41237-57 |
| PubMed ID | 26517809 | Mgi Jnum | J:317005 |
| Mgi Id | MGI:6843975 | Doi | 10.18632/oncotarget.5652 |
| Citation | De Robertis M, et al. (2015) Novel insights into Notum and glypicans regulation in colorectal cancer. Oncotarget 6(38):41237-57 |
| abstractText | The connection between colorectal cancer (CRC) and Wnt signaling pathway activation is well known, but full elucidation of the underlying regulation of the Wnt/beta-catenin pathway and its biological functions in CRC pathogenesis is still needed. Here, the azoxymethane/dextran sulfate sodium salt (AOM/DSS) murine model has been used as an experimental platform able to mimic human sporadic CRC development with predictable timing. We performed genome-wide expression profiling of AOM/DSS-induced tumors and normal colon mucosa to identify potential novel CRC biomarkers. Remarkably, the enhanced expression of Notum, a conserved feedback antagonist of Wnt, was observed in tumors along with alterations in Glypican-1 and Glypican-3 levels. These findings were confirmed in a set of human CRC samples. Here, we provide the first demonstration of significant changes in Notum and glypicans gene expression during CRC development and present evidence to suggest them as potential new biomarkers of CRC pathogenesis. |
